<unk>  proved its noninferiority to linezolid in two phase-III trials, known as the ESTABLISH trials.<unk>  is the second treatment approved by the FDA under the new federal law Generating Antibiotic Incentives Now (known as the GAIN Act). New antibiotics manufactured under this new act will be designed as a Qualified Infectious Disease Product (QIDP), allowing an expedited review by the FDA and an additional five years of market exclusivity.
Tedizolid
Telithromycin
Roxithromycin
Azithromycin
Dirithromycin
Rifampicin
Cadazolid
Gemifloxacin